

Vision to Cure

We have committed \$20 million to blood cancer research since 2005, including \$4.3 million for fifty nine projects in 2011.

GRANTS IN AID

**Ass Prof R Lock, Dr W Kaplan
and Dr Hernán Carol**

Children's Cancer Institute Australia, NSW

Improving treatment options for relapsed T-cell acute lymphoblastic leukaemia

\$198,749 – Jan 2011 to Dec 2012

Prof I Alexander and Prof R Reddel

The Children's Hospital at Westmead, NSW

The risk of cancer in emerging cell-based therapies

\$100,000 – Jan to Dec 2011

Dr J Dickinson et al.

Menzies Research Institute, TAS

Finding causative genes for blood cancers

\$ 91 000 – Jan to Dec 2011

Dr M Guthridge

Australian Centre for Blood Diseases/Monash University, VIC

New approaches to targeting the survival of AML cells

\$99,736 – Jan to Dec 2011

Ass Prof D Curtis and Prof S Jane

Walter and Eliza Hall Institute, VIC

Testing small molecules that inhibit an enzyme expressed in CLL

\$95,239 – Jan to Dec 2011

Prof D Gottlieb

Westmead Millennium Institute, NSW

A way of using a patient's own immune system to stop severe infections caused by potent treatment given to patients with CLL \$ 100,000 - Jan to Dec 2011

Ass Prof B Kuss and Dr S Grist

Flinders Medical Centre, SA

Improving prognostic assessment of CLL by an analysis of DNA repair

\$100,000– Jan to Dec 2010

Prof R Christopherson and Ass Prof S Mulligan

University of Sydney/Kolling Institute, NSW

Predicting risk and treatment response from patterns of surface markers on CLL

\$75,000 – Jan to Dec 2011

Ass Prof B Kuss and Dr S Grist

Flinders Medical Centre, SA

Identifying patients at high risk of relapse in chronic lymphocytic leukaemia

\$25,000 – Jan to Dec 2011

Prof G Hill, Dr K MacDonald and K Markey

Queensland Institute of Medical Research, QLD

Immune competence following bone marrow transplantation

\$ 99 500– Jan to Dec 2011

Dr P Mollee et al.

Princess Alexandra Hospital, QLD

A clinical trial to improve the treatment of AL Amyloidosis

\$100,000– Jan to Dec 2011

Ass Prof N Waterhouse

Mater Medical Research Institute, QLD

How cells of the body's immune system kill blood related malignancies.

\$ 90,000 – Jan to Dec 2011

Dr M McCormack and Dr C Slake

Royal Melbourne Hospital/

Rotary Bone Marrow Institute, VIC

Targeting stem cells that cause T-cell leukaemia

\$ 100,000 – Jan to Dec 2011

Dr A Wei and Prof Christina Mitchell

Monash University/The Alfred Hospital, VIC

Defining the role of inositol phosphatases as collaborators in acute leukaemia

\$100,000 – Jan to Dec 2011

Dr S Ting and Dr S Russell

Peter MacCallum Cancer Centre, VIC

Understanding how blood and leukaemia stem cells function

\$100,000 – Jan to Dec 2011

Dr R Tothill et al.

Peter MacCallum Cancer Centre, VIC

Deciphering the genetic cause of blood cancers to design better treatments

\$ 100,000 – Jan to Dec 2011

An independent panel of leading Australian haematologists and medical scientists advise us. This is our way of ensuring the best projects in priority areas, get the financial backing they need.

Ass Prof D White and Prof T Hughes

Centre for Cancer Biology, SA

Which kinase inhibitor is best for which CP-CML patient?

\$99,254 – Jan to Dec 2011

CLINICAL TRIAL GRANT

Dr A Wei and Prof A Spencer

The Alfred Hospital

Investigating the role of targeted therapy with the FLT3 inhibitor for AML patients with FLT3 mutations

\$ 599,500 – Jan 2011 to Dec 2013

POST DOCTORAL FELLOWSHIPS

Partnership with Cure Cancer Australia Foundation

Dr Stephen Lane

Queensland Institute of Medical Research, QLD

Treatment of blood diseases by targeting the disease-causing stem cells

\$300,000 – Jan 2011 to Dec 2013

Dr A Ng

Walter and Eliza Hall Institute, VIC

Identification of genetic interactions predisposing to leukaemia

\$300,000 – Jan 2011 to Dec 2013

Dr F Tzelepis

The University of Newcastle, NSW

Blood cancer patients' perceptions about the quality of care they receive

\$ 284,169 – Jan 2011 to Dec 2013

PHD SCHOLARSHIPS

Ms N Anstee

Walter and Eliza Hall Institute, VIC

Genetic changes promoting acute myeloid leukaemia and its resistance to therapy

\$120,000 – Jan 2011 to Dec 2013

Ms N Christie

Centre for Cancer Biology, SA

The role of the interleukin-3 receptor on AML stem cells

\$120,000 – Jan 2011 to Dec 2013

Ms J Devlin

Peter MacCallum Cancer Centre, VIC

Inhibiting cell signalling decreases ribosome synthesis and kills lymphoma cells.

\$120,000 – Jan 2011 to Dec 2013

Ms M Lefebure

Peter MacCallum Cancer Centre, VIC

Investigating combinations of drugs for the treatment of an incurable blood cancer \$120,000 – Jan 2011 to Dec 2013

Ms H Lim

St Vincent's Institute, VIC

Roles of the bone and blood vessels in the development of blood disease

\$120,000 – Jan 2011 to Dec 2013

PHD (CLINICAL) SCHOLARSHIPS

Dr A Guirguis

Monash University, VIC

Targeting mechanisms of early cell death in myelodysplasia

\$165,000 – Jan 2011 to Dec 2013

Dr T Teh

The Alfred Hospital, VIC

The role of a new potential therapeutic target that promotes survival of leukaemia cells

\$165,000 – Jan 2011 to Dec 2013

HONOURS SCHOLARSHIPS

Ms T Nababan

Western Australian Institute for Medical Research, WA

How MLF1 affects blood stem cells

\$10,000 – Jan to Dec 2011

CAREER ESTABLISHMENT GRANT

Dr Christina Brown

Royal Prince Alfred Hospital, NSW

Role of microRNAs in Acute Promyelocytic Leukaemia

\$150,000 – Jan 2011 to Dec 2013

CANCER AUSTRALIA PDCCRS FUNDING PARTNERSHIP

Professor Angel Lopez

Centre for Cancer Biology, SA

The role of CD123 in MDS and AML

\$575,000 – Jan 2011 to Dec 2013